Blood test may help tell apart two forms of diabetes
NCT ID NCT03396146
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at whether measuring pancreatic polypeptide levels after a meal can help doctors tell the difference between type 1 diabetes and type 3c diabetes (caused by pancreas damage). Thirty-six adults with either type 1 or type 3c diabetes gave blood and stool samples. The goal was to see if this simple test could improve diabetes classification and guide treatment.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could help doctors more accurately classify diabetes types, leading to better tailored treatment plans.
- What could go wrong
- This is a small, observational study with only 36 participants, so results may not apply broadly. It does not test a new treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
36 people
The number who actually took part.
- Started
-
Jun 2018
- Finished
-
Dec 2019
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients aged 18 years or older * Patients with type 1 diabetes with anti-GAD and / or IA2 and / or Znt8 positive antibodies, or characteristic clinical history, with and without exocrine deficiency (\*) * Patients with chronic alcoholic pancreatitis or cystic fibrosis origin (type 3c diabetes), complicated with diabetes defined by HbA1c\> 6.5% or treated with oral anti-diabetic and / or insulin * Patients who have given informed and written consent to participate in research * Patients affiliated to a social security scheme (\*): The exocrine deficiency is defined by an assay of fecal elastase: * without deficit of exocrine function = fecal elastase = /\> 100 μg / g * with deficit of exocrine function = fecal elastase \<100 μg / g Exclusion Criteria: * Pregnancy * Severe renal impairment (eDFG \<45 mL / min / 1.73 m²)
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE1DIABETES are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cochin Hospital
Paris, Paris, 75014, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new sensor track blood sugar with pinpoint accuracy?
- Can a Normal-Weight baseline improve heart risk assessment in type 1 diabetes?
- Carb showdown: which diet best controls type 1 diabetes?
- Morning workout may burn more fat and stabilize blood sugar in type 1 diabetes
- Could a simple sugar help people with type 1 diabetes exercise safely?
- New study asks: is this glucose monitor a Game-Changer for diabetes?